Status: Recruiting
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Participants needed: 28
Trial details
Phase: Phase 2, Phase 3Age: 0-17Biological sex: AllType: InterventionalSponsor: Calcilytix Therapeutics, Inc., a BridgeBio companyUpdated: Apr 22, 2026Locations: 6
Eligibility criteria
Provide written informed consent (if legally permitted), or have written informe... [+3]
History of thyroid or parathyroid surgery [+6]